Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...
Combining GLP-1 agonists with progestins lowered endometrial cancer risk by 66% compared to progestins alone. The GLP-1 agonist/progestin combination outperformed metformin/progestins in reducing ...
—Study findings highlight the need for improved recommendations of guideline-directed therapies and support the consideration of dual therapy in appropriately selected high-risk patients. In a study ...
GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research Network, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results